How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9496"
  ["article_id"]=>
  string(4) "9496"
  [1]=>
  string(74) "BRIEF—Collategene sales rights deal terminated in Japan and the USA"
  ["article_title"]=>
  string(74) "BRIEF—Collategene sales rights deal terminated in Japan and the USA"
  [2]=>
  string(150) "Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene ("
  ["short_description"]=>
  string(150) "Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene ("
  [3]=>
  string(261) "Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. "
  ["description"]=>
  string(261) "Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(93) "https://www.thepharmaletter.com/collategene-sales-rights-deal-terminated-in-japan-and-the-usa"
  ["blog_url"]=>
  string(93) "https://www.thepharmaletter.com/collategene-sales-rights-deal-terminated-in-japan-and-the-usa"
  [15]=>
  string(19) "2024-08-23 23:29:35"
  ["add_date"]=>
  string(19) "2024-08-23 23:29:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

BRIEF—Collategene sales rights deal terminated in Japan and the USA

Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene 

array(40) {
  [0]=>
  string(4) "9319"
  ["article_id"]=>
  string(4) "9319"
  [1]=>
  string(48) "Regulatory Update — Week of Aug. 19, 2024"
  ["article_title"]=>
  string(48) "Regulatory Update — Week of Aug. 19, 2024"
  [2]=>
  string(153) "&#nl        This week, the FDA published final guidance on product-specific guidance meetings between FDA and ANDA applicants and an electronic submissio"
  ["short_description"]=>
  string(153) "&#nl        This week, the FDA published final guidance on product-specific guidance meetings between FDA and ANDA applicants and an electronic submissio"
  [3]=>
  string(315) "&#nl        This week, the FDA published final guidance on product-specific guidance meetings between FDA and ANDA applicants and an electronic submission template for medical device de novo requests. Draft guidance was published on change control plans for medical devices and product-specific guidances.&#nl      "
  ["description"]=>
  string(315) "&#nl        This week, the FDA published final guidance on product-specific guidance meetings between FDA and ANDA applicants and an electronic submission template for medical device de novo requests. Draft guidance was published on change control plans for medical devices and product-specific guidances.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(77) "https://www.fdanews.com/articles/214046-regulatory-update-week-of-aug-19-2024"
  ["blog_url"]=>
  string(77) "https://www.fdanews.com/articles/214046-regulatory-update-week-of-aug-19-2024"
  [15]=>
  string(19) "2024-08-23 23:23:27"
  ["add_date"]=>
  string(19) "2024-08-23 23:23:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Regulatory Update — Week of Aug. 19, 2024

&#nl This week, the FDA published final guidance on product-specific guidance meetings between FDA and ANDA appli

array(40) {
  [0]=>
  string(4) "9320"
  ["article_id"]=>
  string(4) "9320"
  [1]=>
  string(46) "Quick Notes: EU Edition — Aug. 23, 2024"
  ["article_title"]=>
  string(46) "Quick Notes: EU Edition — Aug. 23, 2024"
  [2]=>
  string(153) "&#nl        In this edition of Quick Notes EU, we note a revised EMA guideline on pharmacovigilance, a call by EMA to revoke authorization of Ocaliva for"
  ["short_description"]=>
  string(153) "&#nl        In this edition of Quick Notes EU, we note a revised EMA guideline on pharmacovigilance, a call by EMA to revoke authorization of Ocaliva for"
  [3]=>
  string(539) "&#nl        In this edition of Quick Notes EU, we note a revised EMA guideline on pharmacovigilance, a call by EMA to revoke authorization of Ocaliva for treatment of primary biliary cholangitis — an autoimmune disease that destroys the liver’s bile ducts, a European Commission survey on electronic instructions for use for medical devices, a new pilot program for developers of orphan medical devices, and a thumbs down in the UK for Enhertu for treatment of HER2-low breast cancer by the National Health Service.&#nl      "
  ["description"]=>
  string(539) "&#nl        In this edition of Quick Notes EU, we note a revised EMA guideline on pharmacovigilance, a call by EMA to revoke authorization of Ocaliva for treatment of primary biliary cholangitis — an autoimmune disease that destroys the liver’s bile ducts, a European Commission survey on electronic instructions for use for medical devices, a new pilot program for developers of orphan medical devices, and a thumbs down in the UK for Enhertu for treatment of HER2-low breast cancer by the National Health Service.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(74) "https://www.fdanews.com/articles/214045-quick-notes-eu-edition-aug-23-2024"
  ["blog_url"]=>
  string(74) "https://www.fdanews.com/articles/214045-quick-notes-eu-edition-aug-23-2024"
  [15]=>
  string(19) "2024-08-23 23:13:00"
  ["add_date"]=>
  string(19) "2024-08-23 23:13:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Quick Notes: EU Edition — Aug. 23, 2024

&#nl In this edition of Quick Notes EU, we note a revised EMA guideline on pharmacovigilance, a call by EMA to re

array(40) {
  [0]=>
  string(4) "9321"
  ["article_id"]=>
  string(4) "9321"
  [1]=>
  string(70) "Lack of CAPAs, MDRs, Complaint Follow-Up, Earn Globus a Warning Letter"
  ["article_title"]=>
  string(70) "Lack of CAPAs, MDRs, Complaint Follow-Up, Earn Globus a Warning Letter"
  [2]=>
  string(158) "&#nl        Globus Medical, a manufacturer of surgical robots, received an FDA Warning Letter after the company’s inadequate response failed to address"
  ["short_description"]=>
  string(158) "&#nl        Globus Medical, a manufacturer of surgical robots, received an FDA Warning Letter after the company’s inadequate response failed to address"
  [3]=>
  string(326) "&#nl        Globus Medical, a manufacturer of surgical robots, received an FDA Warning Letter after the company’s inadequate response failed to address findings regarding screws misplaced during surgeries, lack of correction and preventive action (CAPA) plans and failure to file medical device reports (MDR).&#nl      "
  ["description"]=>
  string(326) "&#nl        Globus Medical, a manufacturer of surgical robots, received an FDA Warning Letter after the company’s inadequate response failed to address findings regarding screws misplaced during surgeries, lack of correction and preventive action (CAPA) plans and failure to file medical device reports (MDR).&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(107) "https://www.fdanews.com/articles/214044-lack-of-capas-mdrs-complaint-follow-up-earn-globus-a-warning-letter"
  ["blog_url"]=>
  string(107) "https://www.fdanews.com/articles/214044-lack-of-capas-mdrs-complaint-follow-up-earn-globus-a-warning-letter"
  [15]=>
  string(19) "2024-08-23 23:03:35"
  ["add_date"]=>
  string(19) "2024-08-23 23:03:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lack of CAPAs, MDRs, Complaint Follow-Up, Earn Globus a Warning Letter

&#nl Globus Medical, a manufacturer of surgical robots, received an FDA Warning Letter after the company’s

array(40) {
  [0]=>
  string(4) "9322"
  ["article_id"]=>
  string(4) "9322"
  [1]=>
  string(68) "FDA Finalizes Guidance on Electronic Submissions for De Novo Devices"
  ["article_title"]=>
  string(68) "FDA Finalizes Guidance on Electronic Submissions for De Novo Devices"
  [2]=>
  string(153) "&#nl        The FDA outlines what goes into a De Novo device request filed using the electronic Submission Template and Resource (eSTAR), in a final guid"
  ["short_description"]=>
  string(153) "&#nl        The FDA outlines what goes into a De Novo device request filed using the electronic Submission Template and Resource (eSTAR), in a final guid"
  [3]=>
  string(186) "&#nl        The FDA outlines what goes into a De Novo device request filed using the electronic Submission Template and Resource (eSTAR), in a final guidance released Thursday.&#nl      "
  ["description"]=>
  string(186) "&#nl        The FDA outlines what goes into a De Novo device request filed using the electronic Submission Template and Resource (eSTAR), in a final guidance released Thursday.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(108) "https://www.fdanews.com/articles/214043-fda-finalizes-guidance-on-electronic-submissions-for-de-novo-devices"
  ["blog_url"]=>
  string(108) "https://www.fdanews.com/articles/214043-fda-finalizes-guidance-on-electronic-submissions-for-de-novo-devices"
  [15]=>
  string(19) "2024-08-23 22:53:08"
  ["add_date"]=>
  string(19) "2024-08-23 22:53:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Finalizes Guidance on Electronic Submissions for De Novo Devices

&#nl The FDA outlines what goes into a De Novo device request filed using the electronic Submission Template and 

array(40) {
  [0]=>
  string(4) "9497"
  ["article_id"]=>
  string(4) "9497"
  [1]=>
  string(34) "J&J gains EC approval for Balversa"
  ["article_title"]=>
  string(34) "J&J gains EC approval for Balversa"
  [2]=>
  string(126) "The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder cancer."
  ["short_description"]=>
  string(126) "The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder cancer."
  [3]=>
  string(126) "The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder cancer."
  ["description"]=>
  string(126) "The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder cancer."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(66) "https://www.thepharmaletter.com/jnj-gains-ec-approval-for-balversa"
  ["blog_url"]=>
  string(66) "https://www.thepharmaletter.com/jnj-gains-ec-approval-for-balversa"
  [15]=>
  string(19) "2024-08-23 21:46:39"
  ["add_date"]=>
  string(19) "2024-08-23 21:46:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

J&J gains EC approval for Balversa

The European Commission (EC) has approved Balversa (erdafitinib) from US healthcare giant Johnson & Johnson in bladder c

array(40) {
  [0]=>
  string(4) "9498"
  ["article_id"]=>
  string(4) "9498"
  [1]=>
  string(52) "EC approval for Moderna’s RSV vaccine mRESVIA"
  ["article_title"]=>
  string(52) "EC approval for Moderna’s RSV vaccine mRESVIA"
  [2]=>
  string(150) "Moderna today received approval from the European Commission (EC) for its mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to p"
  ["short_description"]=>
  string(150) "Moderna today received approval from the European Commission (EC) for its mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to p"
  [3]=>
  string(250) "Moderna today received approval from the European Commission (EC) for its mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. "
  ["description"]=>
  string(250) "Moderna today received approval from the European Commission (EC) for its mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(76) "https://www.thepharmaletter.com/ec-approval-for-modernas-rsv-vaccine-mresvia"
  ["blog_url"]=>
  string(76) "https://www.thepharmaletter.com/ec-approval-for-modernas-rsv-vaccine-mresvia"
  [15]=>
  string(19) "2024-08-23 21:13:12"
  ["add_date"]=>
  string(19) "2024-08-23 21:13:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EC approval for Moderna’s RSV vaccine mRESVIA

Moderna today received approval from the European Commission (EC) for its mRESVIA (mRNA-1345), an mRNA respiratory syncy

array(40) {
  [0]=>
  string(4) "9499"
  ["article_id"]=>
  string(4) "9499"
  [1]=>
  string(54) "US FDA panel to review approach to checkpoint blockers"
  ["article_title"]=>
  string(54) "US FDA panel to review approach to checkpoint blockers"
  [2]=>
  string(150) "The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use of predictive biomarkers for im"
  ["short_description"]=>
  string(150) "The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use of predictive biomarkers for im"
  [3]=>
  string(181) "The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use of predictive biomarkers for immune checkpoint inhibitors.&#nl"
  ["description"]=>
  string(181) "The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use of predictive biomarkers for immune checkpoint inhibitors.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(100) "https://www.thepharmaletter.com/biotechnology/us-fda-panel-to-review-approach-to-checkpoint-blockers"
  ["blog_url"]=>
  string(100) "https://www.thepharmaletter.com/biotechnology/us-fda-panel-to-review-approach-to-checkpoint-blockers"
  [15]=>
  string(19) "2024-08-23 20:26:55"
  ["add_date"]=>
  string(19) "2024-08-23 20:26:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

US FDA panel to review approach to checkpoint blockers

The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use o

array(40) {
  [0]=>
  string(4) "9349"
  ["article_id"]=>
  string(4) "9349"
  [1]=>
  string(454) "キング・ファイサル・スペシャリスト病院・研究センター (King Faisal Specialist Hospital and Research Centre、KFSHRC)、2024年欧州医学教育学会 (AMEE 2024) においてVR技術を用いた新たな世界基準を設定"
  ["article_title"]=>
  string(454) "キング・ファイサル・スペシャリスト病院・研究センター (King Faisal Specialist Hospital and Research Centre、KFSHRC)、2024年欧州医学教育学会 (AMEE 2024) においてVR技術を用いた新たな世界基準を設定"
  [2]=>
  string(282) "サウジアラビア・リヤド発, Aug.  23, 2024  (GLOBE NEWSWIRE) -- KFSHRCは、新しい技術を継続的に採用することで、研修生ã"
  ["short_description"]=>
  string(282) "サウジアラビア・リヤド発, Aug.  23, 2024  (GLOBE NEWSWIRE) -- KFSHRCは、新しい技術を継続的に採用することで、研修生ã"
  [3]=>
  string(1127) "
サウジアラビア・リヤド発, Aug.  23, 2024  (GLOBE NEWSWIRE) -- KFSHRCは、新しい技術を継続的に採用することで、研修生が今日の医療の課題に十分に備え、医療の未来をリードするために必要なスキルと知識を身に付けられるようにしている。 これらの技術は、理論と実践のギャップを埋め、ますます複雑で技術主導の医療環境において主導権を握ることができる医療専門家を準備するものである。
"
  ["description"]=>
  string(1127) "
サウジアラビア・リヤド発, Aug.  23, 2024  (GLOBE NEWSWIRE) -- KFSHRCは、新しい技術を継続的に採用することで、研修生が今日の医療の課題に十分に備え、医療の未来をリードするために必要なスキルと知識を身に付けられるようにしている。 これらの技術は、理論と実践のギャップを埋め、ますます複雑で技術主導の医療環境において主導権を握ることができる医療専門家を準備するものである。
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(300) "https://www.globenewswire.com/news-release/2024/08/23/2934883/0/ja/%E3%82%AD%E3%83%B3%E3%82%B0-%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B5%E3%83%AB-%E3%82%B9%E3%83%9A%E3%82%B7%E3%83%A3%E3%83%AA%E3%82%B9%E3%83%88%E7%97%85%E9%99%A2-%E7%A0%94%E7%A9%B6%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC-King-Faisal-Specialist"
  ["blog_url"]=>
  string(300) "https://www.globenewswire.com/news-release/2024/08/23/2934883/0/ja/%E3%82%AD%E3%83%B3%E3%82%B0-%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B5%E3%83%AB-%E3%82%B9%E3%83%9A%E3%82%B7%E3%83%A3%E3%83%AA%E3%82%B9%E3%83%88%E7%97%85%E9%99%A2-%E7%A0%94%E7%A9%B6%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC-King-Faisal-Specialist"
  [15]=>
  string(19) "2024-08-23 20:15:00"
  ["add_date"]=>
  string(19) "2024-08-23 20:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

キング・ファイサル・スペシãƒ

サウジアラビア・リヤド発, Aug. 23, 2024 (GLOBE NEWSWIRE) --

array(40) {
  [0]=>
  string(4) "9350"
  ["article_id"]=>
  string(4) "9350"
  [1]=>
  string(313) "킹 파이살 전문 병원 겸 연구센터 (KFSHRC), AMEE 2024 (유럽 국제의학교육협회)에서 VR 기술 선보이며 새로운 글로벌 스탠다드 수립"
  ["article_title"]=>
  string(313) "킹 파이살 전문 병원 겸 연구센터 (KFSHRC), AMEE 2024 (유럽 국제의학교육협회)에서 VR 기술 선보이며 새로운 글로벌 스탠다드 수립"
  [2]=>
  string(197) "RIYADH, Saudi Arabia, Aug.  23, 2024  (GLOBE NEWSWIRE) -- 킹 파이살 전문 병원 겸 연구 센터 (King Faisal Specialist Hospital & Researc"
  ["short_description"]=>
  string(197) "RIYADH, Saudi Arabia, Aug.  23, 2024  (GLOBE NEWSWIRE) -- 킹 파이살 전문 병원 겸 연구 센터 (King Faisal Specialist Hospital & Researc"
  [3]=>
  string(1191) "
RIYADH, Saudi Arabia, Aug.  23, 2024  (GLOBE NEWSWIRE) -- 킹 파이살 전문 병원 겸 연구 센터 (King Faisal Specialist Hospital & Research Centre, KFSHRC) 가 새로운 기술의 지속적인 도입을 통해 전공의들이 오늘날 의료 현장 문제에 보다 잘 대비하고 미래 의학 선도에 필요한 기술 및 지식을 보다 잘 갖출 수 있도록 지원하고 있다. 이 같은 기술을 통해 이론과 실무 사이의 간극을 메우는 것은 물론 의료 전문가들은 점점 더 복잡해지는 기술 중심의 의료 환경을 주도해 나가는 데 있어 준비할 수 있게 되는 것이다.
"
  ["description"]=>
  string(1191) "
RIYADH, Saudi Arabia, Aug.  23, 2024  (GLOBE NEWSWIRE) -- 킹 파이살 전문 병원 겸 연구 센터 (King Faisal Specialist Hospital & Research Centre, KFSHRC) 가 새로운 기술의 지속적인 도입을 통해 전공의들이 오늘날 의료 현장 문제에 보다 잘 대비하고 미래 의학 선도에 필요한 기술 및 지식을 보다 잘 갖출 수 있도록 지원하고 있다. 이 같은 기술을 통해 이론과 실무 사이의 간극을 메우는 것은 물론 의료 전문가들은 점점 더 복잡해지는 기술 중심의 의료 환경을 주도해 나가는 데 있어 준비할 수 있게 되는 것이다.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(300) "https://www.globenewswire.com/news-release/2024/08/23/2934883/0/ko/%ED%82%B9-%ED%8C%8C%EC%9D%B4%EC%82%B4-%EC%A0%84%EB%AC%B8-%EB%B3%91%EC%9B%90-%EA%B2%B8-%EC%97%B0%EA%B5%AC%EC%84%BC%ED%84%B0-KFSHRC-AMEE-2024-%EC%9C%A0%EB%9F%BD-%EA%B5%AD%EC%A0%9C%EC%9D%98%ED%95%99%EA%B5%90%EC%9C%A1%ED%98%91%ED%9A%8C-%"
  ["blog_url"]=>
  string(300) "https://www.globenewswire.com/news-release/2024/08/23/2934883/0/ko/%ED%82%B9-%ED%8C%8C%EC%9D%B4%EC%82%B4-%EC%A0%84%EB%AC%B8-%EB%B3%91%EC%9B%90-%EA%B2%B8-%EC%97%B0%EA%B5%AC%EC%84%BC%ED%84%B0-KFSHRC-AMEE-2024-%EC%9C%A0%EB%9F%BD-%EA%B5%AD%EC%A0%9C%EC%9D%98%ED%95%99%EA%B5%90%EC%9C%A1%ED%98%91%ED%9A%8C-%"
  [15]=>
  string(19) "2024-08-23 20:15:00"
  ["add_date"]=>
  string(19) "2024-08-23 20:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

킹 파이살 전문 병원 겸 연구센í„

RIYADH, Saudi Arabia, Aug. 23, 2024 (GLOBE NEWSWIRE) -- 킹 파이살 전문 병원 ê

array(40) {
  [0]=>
  string(4) "9500"
  ["article_id"]=>
  string(4) "9500"
  [1]=>
  string(48) "US pricing watchdog says Rytelo is too expensive"
  ["article_title"]=>
  string(48) "US pricing watchdog says Rytelo is too expensive"
  [2]=>
  string(150) "The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical effectiveness and value of Rytel"
  ["short_description"]=>
  string(150) "The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical effectiveness and value of Rytel"
  [3]=>
  string(246) "The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical effectiveness and value of Rytelo (imetelstat), raising concerns about the drug's net health benefits and its high cost.&#nl"
  ["description"]=>
  string(246) "The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical effectiveness and value of Rytelo (imetelstat), raising concerns about the drug's net health benefits and its high cost.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(95) "https://www.thepharmaletter.com/pharmaceutical/us-pricing-watchdog-says-rytelo-is-too-expensive"
  ["blog_url"]=>
  string(95) "https://www.thepharmaletter.com/pharmaceutical/us-pricing-watchdog-says-rytelo-is-too-expensive"
  [15]=>
  string(19) "2024-08-23 20:14:54"
  ["add_date"]=>
  string(19) "2024-08-23 20:14:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

US pricing watchdog says Rytelo is too expensive

The Institute for Clinical and Economic Review (ICER) has published its final evidence report evaluating the clinical ef

array(40) {
  [0]=>
  string(4) "9315"
  ["article_id"]=>
  string(4) "9315"
  [1]=>
  string(64) "Association for Medical Education in Europe AMEE 2024 conference"
  ["article_title"]=>
  string(64) "Association for Medical Education in Europe AMEE 2024 conference"
  [2]=>
  string(75) "The conference will be held in Basel, Switzerland from 26-28 August&#nl&#nl"
  ["short_description"]=>
  string(75) "The conference will be held in Basel, Switzerland from 26-28 August&#nl&#nl"
  [3]=>
  string(215) "
The conference will be held in Basel, Switzerland from 26-28 August
&#nl
&#nl"
  ["description"]=>
  string(215) "
The conference will be held in Basel, Switzerland from 26-28 August
&#nl
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(94) "https://pharmatimes.com/news/association-for-medical-education-in-europe-amee-2024-conference/"
  ["blog_url"]=>
  string(94) "https://pharmatimes.com/news/association-for-medical-education-in-europe-amee-2024-conference/"
  [15]=>
  string(19) "2024-08-23 19:51:10"
  ["add_date"]=>
  string(19) "2024-08-23 19:51:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:00"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Association for Medical Education in Europe AMEE 2024 conference

The conference will be held in Basel, Switzerland from 26-28 August

&#nl